AR and prostate adenocarcinoma: As is well documented, aberrant activation of AR signaling could drive the progression and ADT resistance of PRAD, which is the main reason that contributes to limited efficacy of treatment (Wen, Niu & Huang, 2020; VanDeusen et al., 2020).